Figure 2 | Scientific Reports

Figure 2

From: The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice

Figure 2

Perampanel administration for 90 days rescued motor dysfunction in AR2 mice.

(a) The time schedule for performance testing and drug treatment. Body weight (b), latency to fall on the rotarod task (c) and grip strength (d) were examined every week throughout the experiment in the perampanel- (n = 8; n = 1 of male, n = 7 of female) and vehicle- (n = 7; n = 3 of male, n = 4 of female) treated AR2 mice. Weekly performance scores are indicated in the upper panels (red bars indicate the first day of administration). Mean values for the four trials before perampanel treatment (pre), initial four trials (1), from the 5th to the 8th trials (2) and from the 9th to the last trails (3) after perampanel treatment are indicated in the lower panels. All data are presented as the mean ± s.e.m. *p < 0.05, **p < 0.001 against the “pre” time point at each time point, one-way ANOVA and Tukey post hoc tests. #p < 0.05 perampanel against the vehicle group at each time point, Wilcoxon rank sum test.

Back to article page